RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Zynerba Pharmaceuticals - Stock

Zynerba Pharmaceuticals Market capitalization 2024

Zynerba Pharmaceuticals Market capitalization

55.46 M USD

Ticker

ZYNE

ISIN

US98986X1090

WKN

A14XCV

In 2024, Zynerba Pharmaceuticals's market cap stood at 55.46 M USD, a 86.09% increase from the 29.8 M USD market cap in the previous year.

The Zynerba Pharmaceuticals Market capitalization history

YEARREVENUE (undefined USD)GROSS MARGIN (%)NET INCOME (undefined USD)
2028e594.44-155.43
2027e372.12-86.38
2026e189.7-28.33
2025e48.86--20.17
2024e11.48--34.52
2023e---46.03
2022---35.04
2021---37.31
2020---51.34
2019---32.94
20180.09--39.91
2017---32.01
20160.01--23.39
20150.28--12.55
20140.81--5.76
20130.94--0.8
20120.6--0.99

Zynerba Pharmaceuticals Aktienanalyse

What does Zynerba Pharmaceuticals do?

Zynerba Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapies for patients with severe central nervous system disorders. The company was founded in 2007 and is headquartered in Devon, Pennsylvania, USA. The history of Zynerba Pharmaceuticals dates back to the discovery by Dr. Magid Abou-Gharbia, who led a team of scientists that developed a method for transporting cannabinoids through the blood-brain barrier. This groundbreaking discovery led to the formation of Zynerba Pharmaceuticals with the goal of developing novel cannabinoid-based therapies. Zynerba Pharmaceuticals' business model is based on the development of medical compounds derived from the cannabis plant. These compounds, known as cannabinoids, have the potential to treat a variety of different conditions related to the central nervous system. The company's strategy is to deliver these compounds in the form of transdermal patches to ensure optimal dosage and absorption by the body. Zynerba Pharmaceuticals is divided into different divisions that focus on specific conditions. The company's main division is the development of therapies for epilepsy based on the cannabinoid Zygel. Zygel is a synthetic cannabinoid administered as a transdermal patch and has high bioavailability. The patch is applied to the skin and delivers a precise dosage of Zygel to reduce seizures in patients with various forms of epilepsy. In addition, Zynerba Pharmaceuticals is working on therapies for neuropsychiatric disorders such as Fragile X syndrome, autism spectrum disorders, and schizophrenia. The company has a promising development pipeline and is currently involved in various clinical trials. The company has achieved many milestones and formed important partnerships to support its innovative research and development. In 2019, Zynerba Pharmaceuticals partnered with the Japanese company Daiichi Sankyo to expand its development pipeline. In summary, Zynerba Pharmaceuticals Inc offers a promising business model for the development of therapies for severe central nervous system disorders based on cannabinoids. The company has a promising development pipeline and has already formed important partnerships to support its research and development. Zynerba Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Zynerba Pharmaceuticals's Market Capitalization

Zynerba Pharmaceuticals's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Zynerba Pharmaceuticals's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Zynerba Pharmaceuticals's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Zynerba Pharmaceuticals’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Zynerba Pharmaceuticals Stock

What is the current Zynerba Pharmaceuticals market capitalization?

The current market capitalization of Zynerba Pharmaceuticals is 55.46 M USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Zynerba Pharmaceuticals.

How has the market capitalization of Zynerba Pharmaceuticals developed in recent years?

The market capitalization of Zynerba Pharmaceuticals has increased/decreased by 86.09% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Zynerba Pharmaceuticals?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Zynerba Pharmaceuticals?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Zynerba Pharmaceuticals have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Zynerba Pharmaceuticals pay?

Over the past 12 months, Zynerba Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zynerba Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Zynerba Pharmaceuticals?

The current dividend yield of Zynerba Pharmaceuticals is .

When does Zynerba Pharmaceuticals pay dividends?

Zynerba Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Zynerba Pharmaceuticals?

Zynerba Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Zynerba Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Zynerba Pharmaceuticals located?

Zynerba Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Zynerba Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Zynerba Pharmaceuticals from 6/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/18/2024.

When did Zynerba Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/18/2024.

What was the dividend of Zynerba Pharmaceuticals in the year 2023?

In the year 2023, Zynerba Pharmaceuticals distributed 0 USD as dividends.

In which currency does Zynerba Pharmaceuticals pay out the dividend?

The dividends of Zynerba Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Zynerba Pharmaceuticals

Our stock analysis for Zynerba Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zynerba Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.